News

Jinse Finance reported that Vitalik Buterin posted on the X platform stating that, in discussions about Ethereum's consensus mechanism, there is a proposal to replace the current finality component Casper FFG with the new Minimmit. He believes that Casper FFG uses a two-round finality mechanism (validators need to sign twice to complete "attestation" and "final confirmation"), while Minimmit requires only one round of signatures to achieve finality. As a trade-off, Minimmit's fault tolerance threshold will decrease from Casper FFG's 33% to about 17%. Although the fault tolerance ratio is reduced, Minimmit is more likely to allow the network to enter a "multi-chain competition rather than incorrect final confirmation" state in various attack or client vulnerability scenarios, a situation that is easier to recover from through community coordination. He believes that, compared to incorrect blocks being finalized, it is safer and more recoverable to have no finality for a short period, and therefore considers Minimmit to be potentially superior in terms of overall security trade-offs.

Bloomberg analyst James Seyffart stated on the X platform that BlackRock has updated its Ethereum staking ETF (ETHB) application documents. The latest documents show that the staking fee rate has been adjusted to 10% of staking rewards, and a tiered fee discount may be offered based on scale. Previously, the documents stated that the staking fee was 18% of total staking returns.

Gelonghui, March 7th｜Hims & Hers Health (HIMS.US) surged more than 35% in after-hours US trading. According to reports, Novo Nordisk plans to sell its weight-loss drugs on the Hims & Hers Health Inc. platform, thereby ending a highly publicized dispute between the two companies that escalated into legal action last month. A source familiar with the matter, who requested anonymity, said Novo Nordisk and Hims could announce the establishment of a new partnership as early as next Monday. The two companies had reached a similar agreement last year, but Novo Nordisk unilaterally terminated the deal after Hims refused to stop marketing and selling generic versions of the drug.